Skip to content

APRE

Aprea Therapeutics, Inc.

NASDAQ · Healthcare · Biotechnology · US

$0.76
+1.32%
Ask drillr
0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
-5.5%
Price return (3m)
Form 4 filings
DateInsiderActivitySharesPrice
Jun 17, 2026BIZZARI JEAN-PIERRE · directorA-Award3,135$0.00
Jun 17, 2026Duey Marc · directorA-Award3,135$0.00
Jun 17, 2026Duey Marc · directorA-Award12,555$0.73
Jun 17, 2026Pamukcu Rifat · directorA-Award3,135$0.00
Jun 17, 2026Pamukcu Rifat · directorA-Award12,555$0.73
Jun 17, 2026Seizinger Bernd R. · directorA-Award3,135$0.00
Jun 17, 2026Seizinger Bernd R. · directorA-Award12,555$0.73
Jun 17, 2026Grissinger Michael · directorA-Award3,135$0.00
Jun 17, 2026Peters Richard · directorA-Award3,135$0.00
Jun 17, 2026Gruia Gabriela · directorA-Award12,555$0.73
Jun 17, 2026Gruia Gabriela · directorA-Award3,135$0.00
Jun 17, 2026Grissinger Michael · directorA-Award12,555$0.73
Jun 17, 2026Peters Richard · directorA-Award12,555$0.73
Jun 17, 2026HENNEMAN JOHN B III · directorA-Award3,135$0.00
Jun 17, 2026HENNEMAN JOHN B III · directorA-Award12,555$0.73
Jun 17, 2026BIZZARI JEAN-PIERRE · directorA-Award12,555$0.73
Mar 16, 2026Hamill John P. · officer: SrVP/CFO/Prin Fin & Acct OfcrA-Award40,380$0.77
Mar 16, 2026Gilad Oren · director, officer: President/CEOA-Award80,700$0.77
Mar 16, 2026Gilad Oren · director, officer: President/CEOA-Award20,175$0.00
Mar 16, 2026Hamill John P. · officer: SrVP/CFO/Prin Fin & Acct OfcrA-Award10,095$0.00
Feb 2, 2026Hamill John P. · officer: SrVP/CFO/Prin Fin & Acct OfcrPurchase5,700$0.89
Feb 2, 2026Gilad Oren · director, officer: President/CEOPurchase28,100$0.89
Dec 11, 2025Gilad Oren · director, officer: President/CEOPurchase21,459$0.00
Dec 11, 2025Duey Marc · directorPurchase21,459$1.17
Dec 11, 2025Hamill John P. · officer: SrVP/CFO/Prin Fin & Acct OfcrPurchase5,000$1.17
Jun 9, 2025Grissinger Michael · directorA-Award4,185$1.81
Jun 9, 2025Pamukcu Rifat · directorA-Award1,045$0.00
Jun 9, 2025Pamukcu Rifat · directorA-Award4,185$1.81
Jun 9, 2025HENNEMAN JOHN B III · directorA-Award1,045$0.00
Jun 9, 2025HENNEMAN JOHN B III · directorA-Award4,185$1.81
Institutional positioning

13F filings over the trailing two quarters

New 15Increased 9Reduced 10Sold out 2
FilerActionSharesFiled
AIGH CAPITAL MANAGEMENT LLCIncreased1,015,541Apr 30, 2026
AIGH Capital Management LLCUnchanged1,015,541Aug 7, 2026
VESTAL POINT CAPITAL, LPNew Position350,000May 15, 2026
Vestal Point Capital, LPUnchanged350,000Aug 14, 2026
SPHERA FUNDS MANAGEMENT LTD.Unchanged270,000May 15, 2026
SPHERA FUNDS MANAGEMENT LTD.Unchanged270,000Aug 14, 2026
Nantahala Capital Management, LLCUnchanged205,760Aug 19, 2026
NANTAHALA CAPITAL MANAGEMENT, LLCUnchanged205,760May 15, 2026
GEODE CAPITAL MANAGEMENT, LLCIncreased119,131May 15, 2026
RENAISSANCE TECHNOLOGIES LLCIncreased105,800Aug 13, 2026
GEODE CAPITAL MANAGEMENT, LLCReduced74,869Aug 12, 2026
SCIENTECH RESEARCH LLCNew Position60,281May 15, 2026
CITADEL ADVISORS LLCNew Position58,600Sep 2, 2026
BNP PARIBAS FINANCIAL MARKETSIncreased45,211Aug 13, 2026
DIADEMA PARTNERS LPNew Position44,907Aug 14, 2026

Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Jun 17, 2026